Is This Battered Growth Stock Still a Buy After Its Latest Stumble?

·4 min read

After reporting worse than anticipated second-quarter earnings on Aug. 8, shares of BioNTech (NASDAQ: BNTX) are tumbling, deepening the stock's decline to 65% over the last 12 months. The culprit is the biotech's lackluster sales of Comirnaty, its coronavirus vaccine developed in conjunction with Pfizer.